Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02SSG
|
|||
| Former ID |
DNC007911
|
|||
| Drug Name |
KYS-05077
|
|||
| Synonyms |
KYS-05077; CHEMBL393304; BDBM50197241; BDBM50005356
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H41N5O
|
|||
| Canonical SMILES |
CN(CCCCCN1CCCC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=CC=C5
|
|||
| InChI |
1S/C33H41N5O/c1-36(21-11-4-12-22-37-23-13-14-24-37)33-35-30-20-10-9-19-29(30)31(38(33)28-17-7-3-8-18-28)25-32(39)34-26-27-15-5-2-6-16-27/h2-3,5-10,15-20,31H,4,11-14,21-26H2,1H3,(H,34,39)
|
|||
| InChIKey |
DKHAGFIMNLTLHC-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Inhibitor | [1] |
| Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Type II diabetes mellitus | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| GABA-B receptor II signaling | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | NCAM signaling for neurite out-growth | |||
| Nicotine Activity on Chromaffin Cells | ||||
| Corticotropin-releasing hormone | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.